Bard Associates’s Cogentix Medical, Inc. CGNT Stock Holding History

Bard Associates’s Portfolio CGNT Stock Details CGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-153,598	Closed	-$484K	–	180
2017 Q4	$484K	Sell	153,598 -1,742	-1%	-$5.02K	0.23%	114
2017 Q3	$398K	Hold	155,340	–	–	0.19%	122
2017 Q2	$270K	Sell	155,340 -726	-0.5%	-$1.25K	0.12%	143
2017 Q1	$281K	Sell	156,066 -6,391	-4%	-$12.6K	0.13%	138
2016 Q4	$327K	Sell	162,457 -9,513	-6%	-$19.4K	0.15%	126
2016 Q3	$313K	Sell	171,970 -1,960	-1%	-$2.54K	0.15%	129
2016 Q2	$167K	Sell	173,930 -9,952	-5%	-$9.82K	0.09%	150
2016 Q1	$202K	Sell	183,882 -3,123	-2%	-$3.51K	0.12%	139
2015 Q4	$241K	Sell	187,005 -22,229	-11%	-$30.4K	0.14%	127
2015 Q3	$259K	Sell	209,234 -3,195	-2%	-$4.9K	0.15%	124
2015 Q2	$344K	Buy	+212,429	New	+$348K	0.17%	121

Other funds holding CGNT

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

GLAM

Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bard Associates's CGNT Position: Q1 2018 in Review

Bard Associates sold out of Cogentix Medical, Inc. (CGNT) in Q1 2018, closing a stake of 153,598 shares — an estimated $484K sold.

Bard Associates first reported a position in CGNT in Q2 2015 and held it in 11 quarters. The position peaked at $484K in Q4 2017. 47 funds tracked by Wall St. Rank hold CGNT as of Q1 2018.

Bard Associates reported no remaining Cogentix Medical, Inc. position as of Q1 2018 after selling out during the quarter.
Bard Associates sold 153,598 Cogentix Medical, Inc. shares in Q1 2018, an estimated $484K.
Bard Associates first reported a position in Cogentix Medical, Inc. in Q2 2015 and held it in 11 quarters.
Bard Associates's Cogentix Medical, Inc. position peaked at $484K in Q4 2017.
47 funds tracked by Wall St. Rank held Cogentix Medical, Inc. as of Q1 2018.

Based on Bard Associates's 13F filing for Q1 2018, filed 14 May 2018.